J&J/Legend’s Carvykti Data Show Earlier-Line Efficacy As Commercial Headwinds Remain

The companies unblinded data from CARTITUDE-4, which met its primary endpoint, but analysts citing KOLs said they continue to face issues with limited manufacturing slots and out-of-spec product.

J&J/Legend announced positive results from the Phase III CARTITUDE-4 study • Source: Shutterstock

Johnson & Johnson’s Janssen Pharmaceutical Cos. and Legend Biotech Corp. have unblinded their Phase III study of the BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel) in patients with second- to fourth-line multiple myeloma after the trial met its primary endpoint. But even if the data give Carvykti a leg up over its main competitor, 2seventy Bio, Inc./Bristol Myers Squibb Company’s Abecma (idecabtagene vicleucel), ongoing production and logistical issues may make the rollout to a larger patient population particularly challenging.

Without disclosing detailed data, J&J and Legend said 27 January that the trial, CARTITUDE-4, met its primary endpoint of showing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Immuno-oncology

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Merus Raises $300m After ASCO Success

 

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

More from Anticancer

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By 

US green light will further expand sales of the prostate cancer blockbuster.

Degron Eyes Deals For Novel Molecular Glue Degrader Assets

 

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.